Fragile X targeted pharmacotherapy: lessons learned and future directions

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Neurodev Disord
Autori principali: Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467059/
https://ncbi.nlm.nih.gov/pubmed/28616096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-017-9186-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi